查詢結果分析
相關文獻
- Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular
- Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer: An Asian Single Institute Experience
- On the Coccinellidae Collected from Areca palm on Hainan Island, China
- 臺灣紅豆杉天然母樹枝葉紫杉醇類含量的變異與選種價值
- 增生性疣性白斑--初期研究
- 檳榔園水文特性之研究
- 新竹市「檳榔景觀」的調查與分析:「環境正義」的觀點
- 認識檳榔棕櫚科之潛在致命殺手--椰子四紋小象鼻蟲及避債蛾
- 乳鹼症--嚼檳榔引起的鈣中毒及鹼中毒
- 吃檳榔對腦神經系統的影響
頁籤選單縮合
題 名 | Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular=Cetuximab為主的治療在復發或轉移的頭頸癌病人:來自嚼食檳榔盛行區的經驗 |
---|---|
作 者 | 張牧新; 謝燿宇; 陳明晃; 曾成槐; 朱本元; 張學逸; 陳博明; 楊慕華; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 73:6 2010.06[民99.06] |
頁 次 | 頁292-299+CA52 |
關鍵詞 | 檳榔; 頭頸癌; 紫杉醇; Cetuximab; Betel nut; Head and neck cancer; Taxane; |
語 文 | 英文(English) |
英文摘要 | Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular. |
本系統中英文摘要資訊取自各篇刊載內容。